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“His book was known as the Book of Sand, because neither the book nor the sand have
any beginning or end.” — Jorge Luis Borges
The human genome is a three billion-letter recipe for the genesis of a human being, directing
development from a single-celled embryo to the trillions of adult cells. Since the sequencing
of the human genome was announced in 2001, researchers have an increased ability to
discern the genetic basis for diseases. This reference genome has opened the door to ge-
nomic medicine, aimed at detecting and understanding all genetic variations of the human
genome that contribute to the manifestation and progression of disease. The overarching vi-
sion of genomic (or “personalized”) medicine is to custom-tailor each treatment for maximum
effectiveness in an individual patient. Detecting the variation in a patient’s deoxyribonucleic
acid (DNA†), ribonucleic acid (RNA), and protein structures is no longer an insurmountable
hurdle. Today, the challenge for genomic medicine lies in contextualizing those myriad ge-
netic variations in terms of their functional consequences for a person’s health and devel-
opment throughout life and in terms of that patient’s susceptibility to disease and differential
clinical responses to medication. Additionally, several recent developments have compli-
cated our understanding of the nominal human genome and, thereby, altered the progres-
sion of genomic medicine. In this brief review, we shall focus on these developments and
examine how they are changing our understanding of our genome.
THE FIVE MODALITIES OF
GENETIC VARIATION
Large-scale genomic variation
In the few years since the release of the
draft human genome sequence, our under-
standing of the importance of this “refer-
ence” genome has changed. Indeed, molec-
ular characterization of karyotypes in the
late1990salreadyrevealedsubstantialchro-
mosomal abnormalities in phenotypically
normal people, a surprising degree of varia-
tion that seemingly conferred no negative
consequences [1]. After a decade of subse-
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present in the human genome, these variable
regions of DNA (called structural variants)
now are thought to cover as much as 20 per-
cent of the length of the human genome.
Thus,dependingonthevariantpresent,some
tensofmillionsofnucleotidescanbemissing
or duplicated — even quadrupled — in any
one person [2]. We now know everyone has
extra copies or missing copies of large parts
of the genome, called copy number variants
(CNVs), and that such large-scale variation
apparently leaves us no worse off.
Rampant small-scale variation
The first diploid sequence of a single
human being has been published [3], further
expanding the amount of observed variation
in a single human genome. Perhaps fittingly,
the genome in question belongs to Craig
Venter, a genome sequencing pioneer and
one of the leaders of the private human
genome consortium that produced a draft se-
quence in 2001. Venter’s genome shows the
initial estimate of similarity between the
genomes of two randomly selected individ-
uals was too high — each person is now
thought to be a mere 99.5 percent similar
rather than the often-quoted 99.9 percent [3].
In total, Venter’s genome has some 4.1 mil-
lion variations with respect to the reference,
totaling 12.3 million base pairs (MB) of se-
quence. This massive amount of divergent
sequence includes hundreds of thousands of
homozygous insertions and deletions (called
“indels”), previously thought to be very rare.
Rogue agents: autonomous, repeated,
and mitochondrial elements
The organization of the human genome
is more complex than initially believed (Fig-
ure 1) [4,5].Aquarter of the genome is ded-
icated to introns, the transcribed but
noncoding parts of genes. Another third of
the genome consists of repeats of varying
kinds. Some repeated sections of the human
genome serve structural purposes (for in-
stance, those located at the ends and in the
middle of chromosomes), but most repeats
are of unknown function and take the form
of simple sequence repeats or larger seg-
mental duplications (SegDups). Counting
toward the one-third of the genome that is
repeated, SegDups (defined as segments at
least 1,000bp long and appear at least twice
throughout the genome) represent 5 percent
of the human genome overall and 15 percent
of all repeated sequence. Some of these seg-
mental duplications hold extra copies of en-
tire genes.
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Figure 1: Structural Divisions of the Human Genome. Most of the human genome con-
sists of repetitive DNA sequences and transposable elements (LINES, SINEs, LTRs, and
viruses). Very little of the genome is coding sequence (exons), but there is great room for
gene flexibility and change with many of the gene’s long intron sequences (introns).Though the majority of the human
genome is repetitive, not all of these repeats
are functionless or inactive. The most ubiq-
uitous repeated genetic elements in the
genome are transposable elements (some-
times called TEs, or transposons), so called
because they can transpose, or jump, from
one place to another in the genome. When
these elements jump, they sometimes create
new forms of genes that may prove useful to
humans; however, depending upon the pre-
cise site of insertion,such genomic shuffling
instead may damage existing genes (for in-
stance, the transposable element might land
in the middle of a functional gene sequence,
disruptingit).Transposableelementsexistin
various forms, including Long Interspersed
Elements (LINEs), Short Interspersed Ele-
ments (SINEs), and the small 300bpAlu el-
ement(consideredaSINE).TheAluelement
is present in 75 percent of introns and ac-
counts for 10 percent of the entire genome,
whereas the 6,000 bp (6 kb) LINEs account
for 20 percent of the human genome and are
present in most human genes. Indeed, when
adding the sequences from repetitive ele-
ments into the size of the genes, introns ac-
count for 37 percent of the human genome,
showing just how prevalent and successful
these transposable elements have been at in-
serting themselves throughout the human
genome over several million years.
Other transposable elements have in-
vaded our genome more recently [6]. Since
our divergence from the common ancestor
we shared with the chimpanzee, approxi-
mately 98,000 viruses have invaded our
genome and are now a part of our species’
genetic code, busily copying themselves and
then re-inserting back into the human
genome. These old viruses, called endoge-
nous retroviruses, total 8 percent of the
human genome (24 percent of all repeated
sequence). These viruses include Long Ter-
minal Repeats (LTRs), which reverse tran-
scribe themselves (from RNA￿ DNA, as
theAIDS virus does), DNAtransposons, and
some viruses that lie dormant and can no
longer replicate themselves (totaling about
4 percent of the human genome, or 12 per-
cent of repeated sequence).
The human genome has also ex-
changed genetic information with the mito-
chondrial genome [7]. To date, the human
genome has been colonized by nearly 300
genes from mitochondria; these genes,
called nuclear DNAof mitochondrial origin
(NUMTs), are expressed by the human
genome for the use of the mitochondria.
Further, 27 of these NUMTs do not appear
in the chimpanzee or other genomes, mean-
ing they have been incorporated into the
human genome within the last 4 to 6 million
years (that is, since the divergence from our
last common ancestor with chimpanzees).
Most of these unique NUMTs (23 of 27) are
present within known or predicted human
genes, indicating that the symbiosis be-
tween these two genomes is very fast evolv-
ing and very gene-centered.
Most of the (nonrepetitive) genome
is transcribed
It has been known since the 1960s that
a significant amount of non-coding DNA
(ncDNA) is transcribed and some of this
leads to the production of functional ncR-
NAs (like ribosomal RNA). However, until
recently, it was not clear what fraction of the
genome was actively processed or how
much of this transcription might contribute
directly to biological function. To address
this and other questions, the ENCODE proj-
ect (the ENCyclopedia of DNA Elements)
was launched in 2003 to identify all the
functional elements in the human genome.
The pilot phase of the ENCODE project was
completed in 2007, and the published results
show that an astonishing 93 percent of the
non-repetitive sequence studied was either
transcriptionally active or otherwise func-
tionally relevant [8,9].This surpassed earlier
estimates, which had suggested that between
30 percent and 60 percent of the genome
was transcriptionally active [10,11,12].
Epigenomics: The mutable backbone
of the genome
The fifth and final modality of variation
for the human genome is that the epigenome
(“epi” is Latin for “above” or “upon”) has a
large role to play in human genetic variation.
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the DNA (methylation) or various changes
to the histones supporting the DNA(methy-
lation, acetylation, phosphorylation, and
ubiquitination), the activity of a gene can be
altered by inhibiting or allowing various
transcription factors access to the targeted
gene sequence. Some diseases now are
being defined not only by catalogued se-
quence mutations, but also by the “epimuta-
tions” that appear to accompany the disease.
These modifications to the epigenome can
be transmitted to offspring in surprisingly
simple ways, such as by a mother’s behavior
during child-rearing [13] or general errors
during egg and sperm production [14]. Be-
cause technologies and methodologies for
studying epigenetics are still in the early
stages, it remains unknown how much these
type of modifications contribute to human
phenotypic variation.
THE LARGER PICTURE: WHAT IT
MEANS FOR THE GENOME
Taken together, these five discoveries
complicate traditional notions of the gene
and our understanding of the genome.While
a clear translational distinction remains be-
tween coding and non-coding genes, we
now know that a large amount of the
genome is transcriptionally active and pro-
duces RNAs that do not fit into current func-
tional categories. As we look closer at the
structure of the human genome, we find it
resembles a patchwork manuscript: a
palimpsest of genetic elements (new and
old, foreign and endogenous) constantly
adapting to fast evolutionary selection pres-
sures, as opposed to an eternal, unchanging
“Book of Life” for our species. Indeed,
when viewed this way, it seems almost
miraculous that this “Book of Sand” [15]
functions at all. For the structurally dynamic
human genome to remain operational, given
our complex neurophysiology and precise
developmental plan, the system must con-
tain either extensive functional redundancy
or a scarcity of critical genetic architectures.
Given the work of the ENCODE Consor-
tium in humans and corroborating evidence
from other species, it now seems likely that
massively parallel functional redundancy is
the most likely explanation. Could critical
genetic architectures — those absolutely in-
tolerant of disruption — really be that
scarce, or are there other reasons why dis-
ruptions of these areas are not seen?
Tests of these two genomic hypotheses
(rarity vs. redundancy as an explanation for
our high tolerance for variation) will occur
within our lifetimes, and these newfound
reservoirs of variation will be needed to gen-
erate an accurate phenotype-to-genotype
map. Indeed, the next step for CraigVenter’s
genome is to probe its cellular function:
Levy and colleagues plan to sample tissues
from each part of Venter’s body and test the
expression of all exons (i.e. the “exome”)
[16]. (Suddenly, volunteering your genome
doesn’t sound like such a good idea.) Com-
piling all this information on genotype (ge-
netic sequence variants such as SNPs,
CNVs, and mutations) and relating it to phe-
notype (enzyme levels, gene expression, and
severity of a disease) is a mammoth under-
taking.This information will need to be con-
textualized and understood before it can be
used to implement genomic medicine, and
the current paucity of such genotype-to-
phenotype databases — as well as the large
amount of work needed to create them —
likely will delay the application of such per-
sonalized care for some time.
However, one thing that can be done
very well with currently available sequence
variantsistotraceanindividual’s familyhis-
toryandancestralroots.Asmentionedprevi-
ously, it is now estimated that any person is
99.5 percent identical, on average, to anyone
else at the genomic level, which translates to
a difference of about one nucleotide per 500
bp.This means an average of sixmillion sin-
gle nucleotide polymorphisms (SNPs) and
othersequencevariantsshouldexistbetween
any two randomly selected human individu-
als. The hunt to characterize these SNPs and
their distribution in various populations
spurred the creation of the haplotype map-
pingproject(HapMap).HapMaphasthusfar
shown that SNPvariation is not random, but
instead can be traced to the likely migration
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during the last 100,000 years. Certain SNPs
and CNVs have been found only within cer-
tainpopulations—thisisparticularlynotice-
able among isolated peoples who have not
interbred with other groups, like theAfrican
Yorubi. More commonly, genetic variants
within a group of people are not binary (i.e.,
simplypresentorabsent),butrathershowan
increasedordecreasedfrequency.Usingonly
10 of these types of markers, called Ances-
try-Informing Markers (AIMs), virtually
anyone can be genotyped into a stereotype.
PHARMACOGENOMICS AND
PERSONALIZED MEDICINE
The five new data and genetic cate-
gories detailed above have created pharma-
cogenomics, a new discipline that draws
upon both pharmacology and genomics. Re-
searchers in this nascent area aim to under-
stand a person’s risk for disease based upon
his or her ancestral genetic roots, plus the ac-
crued genetic variation within that person’s
lifetime (i.e., mutations since birth). They
then hope to tailor medications to the indi-
vidual in consideration of these genetic vari-
ations. Because many commonly used drugs
are not equally effective in all patients, it is
hoped that a more thorough understanding
of the genetic underpinnings to a given dis-
ease will enable more accurate diagnosis and
treatment. For example, two commonly used
cancer drugs, Gleevec [17] and Herceptin
[18], have been shown to be substantially
more effective if certain genes are being ex-
pressed or protein conformations are pres-
ent. The promise of personalized genomic
medicine has prompted the creation of the
Personal Genome Project at Harvard Uni-
versity (as distinguished from the Human
Genome Project, which is concerned with
the genetic component of our species as a
whole), and volunteers are encouraged to
submit genetic samples for whole-genome
sequencing, which is accompanied by a rig-
orous examination and physical characteri-
zation (MRIs, blood tests, medical records).
It also prompted action in the United States
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Figure 2: Number of Life-Based Patents. Genes, their regulatory sequences, and gene
expression profiles account for the bulk of life-based patents, followed by protein-protein
interactions. Haplotypes and SNPs, which will become critical for pharmacogenomics,
have just begun to be patented. Three major biochemical pathways (inset) also have
nearly 1,000 patents issued [23].Senate by Senator Barack Obama, who in-
troduced a bill to procure more federal fund-
ing for such research [19].
Bio-patenting: An obstacle to
personalized medicine?
Pharmacogenomics research does pres-
ent problems, however. Whenever any sig-
nificant disease marker is found, it is
generally patented immediately, potentially
frustrating future research. Notable exam-
ples of this patent rush include the BRCA
gene (Myriad Genetics), Canavan Disease
gene (MCH), and Hepatitis C marker geno-
types (Roche). If researchers from another
laboratory or organization wish to look for
additional markers or mutations within these
genes, they may be infringing these patents
and could face legal action. Unless a specific
policy of open licensing for a patent is cre-
ated, downstream research on these genes
may effectively be blocked. The number of
human genes patented today exceeds 20 per-
cent of all known genes in the genome [20],
and already many patents have been issued
on entire biochemical pathways, such as
NF-κB [21] (Figure 2). Some preliminary
evidence suggests that such “patent thickets”
may negatively impact further research and
knowledge dissemination, which are, of
course, critical to scientific progress [22].
SUMMARY
The technologies and discoveries dis-
cussed here open the door to new questions
in genomics.Along with incremental knowl-
edge of genotype-to-phenotype matches
comes a new set of issues: scientific, legal,
and ethical. At a crime scene, for instance,
should sweeps of genomic DNAsamples be
permitted, as we now demand of finger-
prints? Will the ability to “read” the genetic
probabilities in an individual’s genome pro-
vide fodder for discrimination? Should it?
Will such knowledge transform parenting
into a series of checkboxes to craft the ideal
child? Vague fear of such eventualities has
been lingering for years, highlighted by the
Genetic Information and Nondiscrimination
Act (GINA), which has been introduced into
Congress every year since 1995. It has yet
to pass both the House and the Senate.
Personalized genomic medicine holds
great promise, but is not without its risks.Any
partitioning of human genetic variation into
separate states (e.g., disease vs. normal) could
be of great benefit to both medicine and sci-
ence. With such information, the population-
specific effects of any ailment could be
modeled and appropriately treated, and those
whose DNAdoes not predispose them to such
diseases can be given the happy news. Still, it
remains unclear how well these ongoing stud-
ies will translate into actual, available treat-
ments for patients. The difficulties for
pharmacogenomicsshouldnotbeunderstated,
giventheemergingcomplexitiesofthegenome
(massive structural variation, large-scale se-
quence variation, pervasive expression of
ncDNA, autonomous transposable elements,
and epigenetic changes). To fully understand
the genotypic risks for a disease, particularly
one with links to multiple interacting loci, sci-
entistswillneedtoaccountandcorrectforallof
these sources of variation. How many of these
solutions will be found and how many obsta-
cles will appear remains to be seen — but as
we consider these questions, the dawn of per-
sonalizedmedicineis showing itsfirstlight.
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